Celgene Corp (CELG) 118.71 $CELG
3 Mega-Cap Stocks That Shouldn't Pay a Dividend
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 8:11AM CDT
Source: Flickr user frankieleon. Dividends are often the foundation upon which the best retirement portfolios are built. Even though a dividend of 2% or 3% annually might not seem like much, the ability to reinvest that dividend back into the same...
AMZN: 445.10 (+55.11), FB: 81.53 (-0.88), CELG: 118.71 (+2.62)
4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
Celgene Signals Bigger Immuno-Oncology Push Into Blood Cancers
EP Vantage - at Seeking Alpha - Sat Apr 25, 9:38AM CDT
Friday's deal between AstraZeneca (NYSE: AZN ) and Celgene (NASDAQ: CELG ) shows that when companies are willing to yield full control of key assets, valuable transactions can be negotiated. AstraZeneca will see its anti-PD-L1 antibody...
AZN: 71.79 (-1.34), CELG: 118.71 (+2.62)
Final Glance: Biotechnology companies
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 71.79 (-1.34), JUNO: 56.66 (-1.06), CELG: 118.71 (+2.62)
After Yesterday's Rally of 2.27% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Apr 24, 3:47PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $115.27 to a high of $120.72. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $116.57 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 118.71 (+2.62)
Watch for Celgene to Potentially Pullback After Gaining 2.27% Yesterday
Comtex SmarTrend(R) - Fri Apr 24, 3:47PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $115.27 to a high of $120.72. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $116.57 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 118.71 (+2.62)
Midday Glance: Biotechnology companies
AP - Fri Apr 24, 12:36PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)
Jim Cramer Loves Regeneron, Sees Shares Headed to $500
at The Street - Fri Apr 24, 10:47AM CDT
TheStreet's Jim Cramer remains bullish on several biotech stocks.
BIIB: 401.71 (-28.57), QQQ: 110.54 (+1.48), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98), GOOGL: 573.66 (+16.20), MSFT: 47.87 (+4.53), INTC: 32.08 (-0.27), GOOG: 565.06 (+18.06), AAPL: 130.28 (+0.61), REGN: 480.09 (+0.01), CELG: 118.71 (+2.62)
Early Glance: Biotechnology companies
AP - Fri Apr 24, 9:55AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)
Watch Out: Barbarians At The Gate For Celgene (CELG)
at The Street - Fri Apr 24, 9:41AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CELG: 118.71 (+2.62)
Bristol-Myers may be mulling bid for Celgene
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:27AM CDT
BMY: 65.80 (-0.20), CELG: 118.71 (+2.62)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
Celgene and MedImmune team up in blood cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 7:15AM CDT
AZN: 71.79 (-1.34), CELG: 118.71 (+2.62)
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers
Business Wire - Fri Apr 24, 12:04AM CDT
--Studies Planned to Start in Second Half 2015
AZN: 71.79 (-1.34), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Biogen Earnings Preview: What To Look For
at Investor's Business Daily - Thu Apr 23, 6:45PM CDT
Biogen (BIIB) on Friday morning is expected to report earnings of $3.91 a share, up 58% vs. a year earlier. That would end a three-quarter string of accelerating growth. Sales should show a 25% advance to $2.66 billion, a solid gain but the fourth...
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
POMALYST(R) (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA
Business Wire - Thu Apr 23, 4:43PM CDT
Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated approval requirements for POMALYST(R) (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma patients. POMALYST, in combination with dexamethasone is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Preview: European Investors Still In Love With North American Equities
Garry Wilson - at Seeking Alpha - Thu Apr 23, 11:41AM CDT
CNX: 30.20 (-0.48), PRGO: 192.89 (-8.74), CAM: 52.81 (+0.03), MKC: 75.84 (-0.38), MON: 118.46 (+0.97), KORS: 63.48 (+0.14), RL: 136.47 (-0.90), DLPH: 83.51 (+0.32), MSI: 60.57 (-0.27), DO: 29.82 (-0.58), MAT: 30.20 (+1.28), NWL: 39.54 (-0.08), THC: 50.65 (-0.58), DNR: 8.10 (-0.31), MA: 90.72 (-0.16), MNK: 122.01 (-2.84), HAR: 145.10 (-1.39), HES: 75.21 (-0.59), PBI: 22.91 (-0.26), UHS: 122.69 (+0.09), EW: 138.33 (-3.59), MHFI: 106.23 (+0.97), CELG: 118.71 (+2.62), MCO: 107.50 (-0.26), MS: 37.36 (-0.02), SYMC: 24.67 (+0.03), UA: 82.56 (-0.70), NTRS: 73.10 (-0.69), ESV: 24.04 (-0.23), SIAL: 139.00 (+0.03), ESS: 227.01 (-0.74), XRAY: 52.42 (+0.30), CTSH: 59.73 (-1.47), NE: 15.67 (-0.40), KMI: 44.34 (-0.23), KEY: 14.23 (-0.11), ADBE: 76.54 (+0.02), KIM: 25.43 (+0.23), PPG: 223.31 (-2.57), APD: 150.06 (-0.54), EMN: 75.47 (+0.17), CF: 294.44 (+4.67), LRCX: 76.70 (-0.38), TSO: 89.63 (+3.13), RHT: 76.83 (-0.02), GM: 35.59 (-0.33), KLAC: 58.89 (-0.96), CELGZ: 2.76 (-0.12), CRM: 67.83 (-0.64)
3 Mega-Cap Stocks That Shouldn't Pay a Dividend
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 8:11AM CDT
Source: Flickr user frankieleon. Dividends are often the foundation upon which the best retirement portfolios are built. Even though a dividend of 2% or 3% annually might not seem like much, the ability to reinvest that dividend back into the same...
AMZN: 445.10 (+55.11), FB: 81.53 (-0.88), CELG: 118.71 (+2.62)
4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
Celgene Signals Bigger Immuno-Oncology Push Into Blood Cancers
EP Vantage - at Seeking Alpha - Sat Apr 25, 9:38AM CDT
Friday's deal between AstraZeneca (NYSE: AZN ) and Celgene (NASDAQ: CELG ) shows that when companies are willing to yield full control of key assets, valuable transactions can be negotiated. AstraZeneca will see its anti-PD-L1 antibody...
AZN: 71.79 (-1.34), CELG: 118.71 (+2.62)
Final Glance: Biotechnology companies
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 71.79 (-1.34), JUNO: 56.66 (-1.06), CELG: 118.71 (+2.62)
After Yesterday's Rally of 2.27% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Apr 24, 3:47PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $115.27 to a high of $120.72. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $116.57 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 118.71 (+2.62)
Watch for Celgene to Potentially Pullback After Gaining 2.27% Yesterday
Comtex SmarTrend(R) - Fri Apr 24, 3:47PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $115.27 to a high of $120.72. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $116.57 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 118.71 (+2.62)
Midday Glance: Biotechnology companies
AP - Fri Apr 24, 12:36PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)
Jim Cramer Loves Regeneron, Sees Shares Headed to $500
at The Street - Fri Apr 24, 10:47AM CDT
TheStreet's Jim Cramer remains bullish on several biotech stocks.
BIIB: 401.71 (-28.57), QQQ: 110.54 (+1.48), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98), GOOGL: 573.66 (+16.20), MSFT: 47.87 (+4.53), INTC: 32.08 (-0.27), GOOG: 565.06 (+18.06), AAPL: 130.28 (+0.61), REGN: 480.09 (+0.01), CELG: 118.71 (+2.62)
Early Glance: Biotechnology companies
AP - Fri Apr 24, 9:55AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)
Watch Out: Barbarians At The Gate For Celgene (CELG)
at The Street - Fri Apr 24, 9:41AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CELG: 118.71 (+2.62)
Bristol-Myers may be mulling bid for Celgene
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:27AM CDT
BMY: 65.80 (-0.20), CELG: 118.71 (+2.62)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
Celgene and MedImmune team up in blood cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 7:15AM CDT
AZN: 71.79 (-1.34), CELG: 118.71 (+2.62)
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers
Business Wire - Fri Apr 24, 12:04AM CDT
--Studies Planned to Start in Second Half 2015
AZN: 71.79 (-1.34), CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Biogen Earnings Preview: What To Look For
at Investor's Business Daily - Thu Apr 23, 6:45PM CDT
Biogen (BIIB) on Friday morning is expected to report earnings of $3.91 a share, up 58% vs. a year earlier. That would end a three-quarter string of accelerating growth. Sales should show a 25% advance to $2.66 billion, a solid gain but the fourth...
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)
POMALYST(R) (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA
Business Wire - Thu Apr 23, 4:43PM CDT
Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated approval requirements for POMALYST(R) (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma patients. POMALYST, in combination with dexamethasone is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
CELG: 118.71 (+2.62), CELGZ: 2.76 (-0.12)
Preview: European Investors Still In Love With North American Equities
Garry Wilson - at Seeking Alpha - Thu Apr 23, 11:41AM CDT
CNX: 30.20 (-0.48), PRGO: 192.89 (-8.74), CAM: 52.81 (+0.03), MKC: 75.84 (-0.38), MON: 118.46 (+0.97), KORS: 63.48 (+0.14), RL: 136.47 (-0.90), DLPH: 83.51 (+0.32), MSI: 60.57 (-0.27), DO: 29.82 (-0.58), MAT: 30.20 (+1.28), NWL: 39.54 (-0.08), THC: 50.65 (-0.58), DNR: 8.10 (-0.31), MA: 90.72 (-0.16), MNK: 122.01 (-2.84), HAR: 145.10 (-1.39), HES: 75.21 (-0.59), PBI: 22.91 (-0.26), UHS: 122.69 (+0.09), EW: 138.33 (-3.59), MHFI: 106.23 (+0.97), CELG: 118.71 (+2.62), MCO: 107.50 (-0.26), MS: 37.36 (-0.02), SYMC: 24.67 (+0.03), UA: 82.56 (-0.70), NTRS: 73.10 (-0.69), ESV: 24.04 (-0.23), SIAL: 139.00 (+0.03), ESS: 227.01 (-0.74), XRAY: 52.42 (+0.30), CTSH: 59.73 (-1.47), NE: 15.67 (-0.40), KMI: 44.34 (-0.23), KEY: 14.23 (-0.11), ADBE: 76.54 (+0.02), KIM: 25.43 (+0.23), PPG: 223.31 (-2.57), APD: 150.06 (-0.54), EMN: 75.47 (+0.17), CF: 294.44 (+4.67), LRCX: 76.70 (-0.38), TSO: 89.63 (+3.13), RHT: 76.83 (-0.02), GM: 35.59 (-0.33), KLAC: 58.89 (-0.96), CELGZ: 2.76 (-0.12), CRM: 67.83 (-0.64)
